Cargando…
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders
BACKGROUND: There is evidence that barriers exist for the initiation of direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) for those with substance use disorders (SUDs). However, real world clinical evidence of DAA treatment initiation following receipt of a prescription and continu...
Autores principales: | Jiang, Xinyi, Song, Hyun Jin, Wang, Wei, Henry, Linda, Childs-Kean, Lindsey M, Re, Vincent Lo, Park, Haesuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244773/ https://www.ncbi.nlm.nih.gov/pubmed/34185563 http://dx.doi.org/10.18553/jmcp.2021.27.7.873 |
Ejemplares similares
-
Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C
por: Jiang, Xinyi, et al.
Publicado: (2021) -
Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
por: Park, Haesuk, et al.
Publicado: (2019) -
Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
por: Park, Haesuk, et al.
Publicado: (2020) -
Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection
por: Park, Haesuk, et al.
Publicado: (2022) -
Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
por: Cartwright, Emily J., et al.
Publicado: (2023)